Original Article High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue

  2015cited by this paper
• Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

  2014cited by this paper
• Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness

  2014cited by this paper
• High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

  2014cited by this paper
• Potential Urinary miRNA Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients

  2014cited by this paper
• Urine microRNAs as potential noninvasive biomarkers in urologic cancers.

  2014cited by this paper
• Prostate-specific antigen and other serum and urine markers in prostate cancer.

  2014cited by this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013cited by this paper
• A review of expression profiling of circulating microRNAs in men with prostate cancer

  2013cited by this paper
• The role of a standardized 36 core template‐assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography‐guided prostate biopsies

  2012cited by this paper
• Chronic prostatitis does not influence urinary PCA3 score

  2012cited by this paper
• Variable prostate-specific antigen management patterns by nonurologist providers at a tertiary care medical center.

  2011cited by this paper
• Focal therapy meets prostate cancer.

  2010cited by this paper
• External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

  2010cited by this paper
• Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

  2010cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

  2008cited by this paper
• Prostatitis/chronic pelvic pain syndrome.

  2006cited by this paper
• The Androgen Axis in Recurrent Prostate Cancer

  2004cited by this paper
• New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.

  2003cited by this paper
• Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

  2003cited by this paper
• DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

  2003cited by this paper
• Screening for prostate cancer with prostate-specific antigen: beware the biases.

  2002cited by this paper
• Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer.

  2000cited by this paper
• Aptima Pca3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer

  year unknowncited by this paper

• No citing papers are available for this paper.